Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24; 375(9724):1437-46.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.